 |
 |
 |
 |
 |
 |
||
 |
 |
 |
 |
 |
| 5 | 1/1 | 返回列表 |
| 查看: 1313 | 回復(fù): 4 | |||
zlwcw木蟲 (著名寫手)
|
[交流]
【討論】2010 制藥公司大裁員意味著 中國的就業(yè)幾率會大幅增加 已有1人參與
|
|
http://blog.pharmexec.com/2010/1 ... ffs-for-big-pharma/ 2010: A Year of Big Layoffs for Big Pharma By Jennifer Ringler | Published: October 19, 2010 What are the factors that are contributing to the layoffs that have taken place at virtually all the Big Pharma companies this year? According to the newly released Job-Cut Announcement Report from outplacement consultancy firm Challenger, Gray & Christmas, pharma has cut more than 6,000 jobs in September alone, and more than 43,000 so far this year. Which companies have contributed to this staggering number, and what are the underlying causes of job losses in the industry? Most recently, Sanofi-Aventis announced its plans to eliminate 1,700 jobs in its US pharma business—about 25 percent of the company’s US pharma workers. The majority of jobs lost will be sales positions, and a small number of administrative jobs will disappear as well. Before that, in September, Roche announced its “Operational Excellence Initiative,” which—while partly intended to analyze and restructure different segments of the company to maximize productivity and ROI—ultimately amounted to job cuts in an effort to “set the right priorities to ensure a successful future,” according to a statement released by Roche. In May, Pfizer announced 6,000 layoffs that it said was part of “manufacturing reorganization” following its 2009 Wyeth acquisition. Possibly part of its plan to remain on track for its targeted cost reduction of $4 to $5 billion by the end of 2012, Pfizer has gone from nearly 114,000 employees internationally in Q 1 2010 to around 33,000 as of May of this year, according to a story on DailyFinance.com. Following its 2009 acquisition of Schering-Plough, Merck began making cuts in February. The post-merger cuts would be a way to “eliminate some of the duplication,” according to a statement made in January by Merck CEO Dick Clark. “We have taken the best from both companies, from a process standpoint and a people standpoint,” he said. And at the start of the year, way back in January, AstraZeneca announced its plan to cut around 8,000 jobs—four percent of its total workforce—over the next four years. As it does for so many Big Pharma players, the patent cliff lies at the heart of the issue. AstraZeneca products scheduled to lose patent protection this year are Armidex, a breast cancer therapy; and Pulmicort Respules, an asthma treatment. Part of the trouble for drug manufacturers is the looming patent expiration dates and impending generics competition. Three of Sanofi’s top products—anticlotting medicines Lovenox and Plavix and cancer drug Taxotere—have or will soon have new generic competition, jeopardizing nearly $10 billion of the company’s $40 billion in annual sales, according to a story on Yahoo! Finance. There are several other factors that are contributing to the layoffs trend: • Structural transformations in the marketplace, focused on the declining relevance of a large sales force in an era of managed care as well as more targeted high-yield approaches to drug development that require less dedicated staff for R&D operations. • Redeployment of assets in line with globalization and the ability to dig deep in untapped growth markets. Job losses in the US and Europe mean that more workers can be hired in countries like China—where, for example, turnover among sales forces is quite high and needs frequent replenishment. • Advances in information technology that improve productivity for a smaller workforce. Information is not only a strategic asset; it is a labor-saving instrument to replace back-office functions and support more automation in manufacturing. • The high cost of producing biologicals drugs are forcing companies to be more selective in where they manufacture, with fewer plants staffed by fewer people with more skills. While such redistribution of assets and focus on greater ROI can be positive for a company as a whole, it can have negative effects on individual workers. In an industry that was once thought to be immune to layoffs, the dynamic can change if workers become wary of job loss, shifting toward a culture of bureaucratic self-preservation that may not always be in line with the importance of fostering entrepreurialism and prudent risk taking. |
回復(fù)此樓» 猜你喜歡
【招聘】清華大學(xué)藥學(xué)院錢鋒教授課題組誠聘博士后
已經(jīng)有1人回復(fù)
-
新版scifinder
已經(jīng)有1人回復(fù)
-
藥理學(xué)論文潤色/翻譯怎么收費?
已經(jīng)有241人回復(fù)
-
安捷倫液相色譜柱與方法開發(fā)指南
已經(jīng)有4人回復(fù)
-
2026年山東大學(xué)海洋學(xué)院生物與醫(yī)藥博士招生-李霞課題組
已經(jīng)有0人回復(fù)
-
博士研究生招生
已經(jīng)有0人回復(fù)
-
2026申請考核博士自薦-蛋白質(zhì)組學(xué)/AI/藥物設(shè)計/AIDD/化學(xué)生物學(xué)
已經(jīng)有1人回復(fù)
-
藥理學(xué)、臨床藥學(xué)方向 調(diào)劑
已經(jīng)有1人回復(fù)
-
廣西醫(yī)科大學(xué)基礎(chǔ)醫(yī)學(xué)院自身免疫病課題組招收基礎(chǔ)醫(yī)學(xué)相關(guān)專業(yè)的調(diào)劑研究生
已經(jīng)有2人回復(fù)
-
中國醫(yī)藥行業(yè)發(fā)展現(xiàn)狀：標(biāo)準(zhǔn)品推動藥品檢測水平提升
已經(jīng)有1人回復(fù)
» 本主題相關(guān)價值貼推薦，對您同樣有幫助:
- 中北大學(xué)化學(xué)工程（專碩）到底怎么樣？就業(yè)形勢如何？
已經(jīng)有20人回復(fù)
- 有機化學(xué)就業(yè)咨詢
已經(jīng)有8人回復(fù)
- 關(guān)于應(yīng)用化學(xué)（偏向材料方向）博士的就業(yè)
已經(jīng)有11人回復(fù)
- FDA對于仿制藥的審評策略
已經(jīng)有70人回復(fù)
- 請問仿制藥研究中需要買原研制劑，買出廠后幾個月的合適
已經(jīng)有6人回復(fù)
- 仿制藥改規(guī)格！
已經(jīng)有23人回復(fù)
- 化學(xué)制藥廠新型設(shè)備交流
已經(jīng)有28人回復(fù)
- 失效模式和效果分析(FMEA)在制藥行業(yè)的應(yīng)用
已經(jīng)有55人回復(fù)
- 《制藥經(jīng)理人》（Pharm Exec)對全球最大的制藥公司前50強的排位
已經(jīng)有76人回復(fù)
- 向大家請教，蘇州有什么好點的化學(xué)和制藥類企業(yè)？？？
已經(jīng)有4人回復(fù)
- 【交流】中檢所無對照品，制藥廠怎么執(zhí)行中國藥典2010版？
已經(jīng)有29人回復(fù)
sdlj82
金蟲 (正式寫手)
每年都拖平均工資的后腿
- 應(yīng)助: 10 (幼兒園)
- 金幣: 1190.6
- 帖子: 394
- 在線: 86.3小時
- 蟲號: 83032
- 注冊: 2005-07-28
- 性別: GG
- 專業(yè): 中藥制劑
2樓2010-10-30 09:32:44
3樓2010-10-30 16:40:35
alipu2008
銅蟲 (初入文壇)
- 應(yīng)助: 0 (幼兒園)
- 金幣: 310.2
- 帖子: 37
- 在線: 59.5小時
- 蟲號: 1129018
- 注冊: 2010-10-22
- 專業(yè): 民族藥學(xué)
4樓2010-10-30 19:56:12
liao_xinglong
鐵桿木蟲 (正式寫手)
- 應(yīng)助: 15 (小學(xué)生)
- 金幣: 6573.3
- 散金: 3
- 帖子: 803
- 在線: 653.8小時
- 蟲號: 246016
- 注冊: 2006-04-29
- 性別: GG
- 專業(yè): 有機合成
5樓2010-11-01 10:49:27
相關(guān)版塊跳轉(zhuǎn)
我要訂閱樓主 zlwcw 的主題更新
| 5 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 285求調(diào)劑 +3 | ytter 2026-03-22 | 3/150 |
|
|---|---|---|---|---|
|
[考研] 考研調(diào)劑 +3 | 呼呼？~+123456 2026-03-21 | 3/150 |
|
|
|
[考研] 0805 316求調(diào)劑 +3 | 大雪深藏 2026-03-18 | 3/150 |
|
|
|
[考研] 材料學(xué)碩333求調(diào)劑 +3 | 北道巷 2026-03-18 | 3/150 |
|
|
|
[考研] 313求調(diào)劑 +4 | 肆叁貳壹22 2026-03-19 | 4/200 |
|
|
|
[考研] 317求調(diào)劑 +9 | 申子申申 2026-03-19 | 15/750 |
|
|
|
[考研] 307求調(diào)劑 +3 | 余意卿 2026-03-18 | 3/150 |
|
|
|
[考研] 266求調(diào)劑 +3 | 哇呼哼呼哼 2026-03-20 | 3/150 |
|
|
|
[考研] 機械專碩299求調(diào)劑至材料 +3 | kkcoco25 2026-03-16 | 4/200 |
|
|
|
[考研] 299求調(diào)劑 +6 | △小透明* 2026-03-17 | 6/300 |
|
|
|
[考研] 一志愿華中科技大學(xué)，080502，354分求調(diào)劑 +5 | 守候夕陽CF 2026-03-18 | 5/250 |
|
|
|
[考研] 304求調(diào)劑 +7 | 司空. 2026-03-18 | 7/350 |
|
|
|
[考研] 求調(diào)劑，一志愿:南京航空航天大學(xué)大學(xué) ，080500材料科學(xué)與工程學(xué)碩，總分289分 +4 | @taotao 2026-03-19 | 4/200 |
|
|
|
[考研] 中南大學(xué)化學(xué)學(xué)碩337求調(diào)劑 +3 | niko- 2026-03-19 | 6/300 |
|
|
|
[考研] 一志愿武理材料工程348求調(diào)劑 +3 | ￣^￣゜汗 2026-03-19 | 4/200 |
|
|
|
[考研] 085600材料與化工調(diào)劑 324分 +10 | llllkkkhh 2026-03-18 | 12/600 |
|
|
|
[考研] 【同濟軟件】軟件（085405）考研求調(diào)劑 +3 | 2026eternal 2026-03-18 | 3/150 |
|
|
|
[考博] 26申博 +4 | 八6八68 2026-03-16 | 4/200 |
|
|
|
[考研] 材料工程專碩274一志愿211求調(diào)劑 +6 | 薛云鵬 2026-03-15 | 6/300 |
|
|
|
[考研] 302求調(diào)劑 +4 | 小賈同學(xué)123 2026-03-15 | 8/400 |
|